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Purpose: To present genome-wide association analyses of genotypic and environmental risks on age-related macular
degeneration (AMD) using 593 subjects from the age-related eye disease study (AREDS), after adjusting for population
stratification and including questionable controls.
Methods: Single nucleotide polymorphism (SNP) associations with AMD for the non-Hispanic white population were
investigated using a log-additive model after adjusting for population stratification. Replication of possible SNP-disease
association was performed by genotyping an independent group of 444 AMD case and 300 control subjects. Logistic
regression models were used to assess interaction effects between smoking and SNPs associated with AMD. Independent
genetic risk effects among the disease-associated SNPs were also investigated using multiple logistic regression models.
Results: Population stratification was observed among the individuals having a self-reported race of non-Hispanic white.
Risk allele frequencies at established AMD loci demonstrated that questionable control subjects were similar to control
subjects in the AREDS, suggesting that they could be used as true controls in the analyses. Genetic loci (complement
factor  H  [CFH],  complement  factor  B  [CFB],  the  age-related  maculopathy  susceptibility  2  locus  containing  the
hypothetical gene [LOC387715]/the high-temperature requirement A-1 [HTRA1], and complement component 3 [C3])
that were already known to be associated with AMD were identified. An additional 26 novel SNPs potentially associated
with AMD were identified, but none were definitely replicated in a second independent group of subjects. Smoking did
not interact with known AMD loci, but was associated with late AMD. Statistically independent genetic signals were
observed within the Pleckstrin homology domain-containing family A member 1 (PLEKHA1) region near LOC387715/
HTRA1 and within a haplotype spanning exon 19 of the C3 gene.
Conclusions:  Population  stratification  among  Caucasian  subjects  from  the  multicentered  AREDS  was  observed,
suggesting that it should be adjusted for in future studies. The AREDS questionable control subjects can be used as control
subjects in the AREDS genome-wide association study (GWAS). Smoking was an independent risk factor for advanced
AMD in the AREDS subjects. There continues to be evidence that the 10q26 (age-related maculopathy susceptibility 2
gene [ARMS2]) locus spanning PLEKHA1-LOC387715-HTRA1 and the C3 gene may contain multiple independent genetic
risks contributing to AMD.
Age-related  macular  degeneration  (AMD)  is  a
progressive  neurodegenerative  disease  that  is  the  leading
cause  of  vision  loss  in  older  individuals  [1].  The  more
advanced forms of AMD are associated with atrophy of the
retinal pigment epithelium (geographic atrophy) or abnormal
angiogenesis (exudation) [2]. AMD is inherited as a complex
disease with multiple genetic and environmental risks [3].
Environmental and lifestyle risk factors that may modify an
individual’s  risk  of  developing  AMD  include  smoking,
alcohol  consumption,  obesity,  a  lower  level  of  physical
activity, and diet [4]. The strongest identifiable risk factors for
AMD  continue  to  be  age,  family  history,  genetics,  and
smoking [5].
Currently,  two  biologic  pathways  contain  genetic
variants  contributing  to  AMD  risk.  Genetic  variations  in
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multiple  complement  genes  [6-12]  and  in  a  locus  on
chromosome 10q26 [13] are major risks for the development
of  AMD.  Variants  in  other  regions  such  as  the  human
leukocyte  antigen  (HLA)  locus,  mitochondrial  genome,
interleukin 8 (IL8), apolipoprotein E (ApoE), and factor I
(FI), may alter the risk of AMD, but additional studies are
needed  due  to  inconsistent  or  absent  replication  in
independent study groups [14-17].
The genetic epidemiology of AMD is currently being
investigated  using  genome-wide  association  studies
(GWASs). The 593 subjects from the age-related eye disease
study (AREDS) were genotyped using the Illumina Human-1
Bead-Chip  panel  containing  109,270  single  nucleotide
polymorphisms (SNPs). The data set was deposited into the
National Center for Biotechnology Information database of
Genotypes and Phenotypes (dbGaP). The AREDS subjects
have  been  used  for  replication  studies  [11,18-20],  meta-
analyses [21], gentic epidemiology [22-24], and candidate
gene selection by us and other investigators [12,21,25,26], but
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2811an analysis of the GWAS that includes strict quality control
and population stratification has not yet been presented.
The AREDS was initiated in 1990 to learn more about the
clinical  course,  prognosis,  and  risk  factors  of  AMD  and
cataract. Over 4,700 people, ages 55 to 80 years, were enrolled
in the AREDS cohort. These individuals were randomized for
treatment with placebo, antioxidants, zinc, or antioxidants
plus zinc, and were followed for a minimum of five years
[27]. Results of the clinical trial suggested that people with a
high risk of developing advanced AMD lowered their risk of
AMD  by  25%  when  they  were  treated  with  a  high  dose
combination of vitamin C, vitamin E, beta-carotene, and zinc
[27]. The AREDS GWAS is a valuable data set because of the
extensive phenotypic and epidemiological variables collected
during the study.
We  present  a  comprehensive  analysis  of  the  AREDS
GWAS  to  search  for  novel  genetic  loci  for  AMD,  their
interactions with smoking, and multiple independent genetic
risks within AMD loci. In doing so, we have applied genotype
quality-control filters and assessed genetic association using
additive models accounting for population stratification. We
have  also  compared  the  questionable  control  group  (see
Methods section) to the control group to determine if they
have allele frequencies at AMD risk loci that are more similar
to true controls or to cases. We attempted replication of all
SNP effects that exceeded a significance level (p value) of less
than 0.0001 in an independent case-control study of AMD,
using logistic regression under an additive genetic model.
METHODS
AREDS subjects and GWAS: We downloaded genotype data
from the AREDS database (NIH-dbGaP), controlled through
dbGaP  accession  number  phs000001.v1.p1.  Of  the  593
subjects included in the AREDS genome-wide scan, 395 cases
and  198  controls  were  successfully  genotyped.  The
distribution  of  AMD  subtypes,  control  subtypes,  smoking
exposure, and race are shown in Table 1. The cases were
graded using standard clinical definitions of AMD [27]. The
control category included subjects with AMD category 1 in
both eyes at all visits. AMD category 1 was defined as any
drusen present being less than 63 μm and the total area of
drusen  being  less  than  the  area  of  a  125  μm  circle.  The
questionable  control  categories  ranged  from  1  to  4.  The
questionable control category 1 is for subjects who have AMD
category  2  at  only  one  visit  except  the  last,  and  the
questionable control category 4 is for those who have AMD
category 2 (small to intermediate drusen) in one eye at the last
vist, but AMD category 1 for both eyes at all other visits.
Replication: SNPs from the AREDS genome-wide scan were
analyzed using logistic regression under an additive genetic
model. Those with p values of less than 0.0001 from loci not
known to contribute to AMD were considered for replication
using an independent sample of AMD cases and controls. The
replication subjects consisted of 744 individuals including
444 AMD cases and 300 controls without AMD. The use of
these subjects was approved by the institutional review board
of the Mayo Clinic, written informed consent was obtained
TABLE 1. SUMMARY OF AGE-RELATED EYE DISEASE STUDY (AREDS) SUBJECTS GENOTYPED ON THE HUMAN 1 BEAD-CHIP PANEL AND THE SUBJECTS USED FOR
REPLICATION.
  AREDS subjects Replication subjects
Variable Cases Controls Cases Controls
Number of AREDS subjects genotyped 395 198 444 300
Early AMD (%) 14 (3.5%) - 202 (45.5%) -
Geographic atrophy (%) 134 (34%) - 67 (15.1%) -
Exudation (%) 197 (49.9%) - 175 (39.4%) -
Both (%) 50 (12.6%) - - -
Control (%) - 171 (86.4%) - 300 (100%)
Questionable control (%) - 27 (13.6%) - -
Mean age (SD) in years 79.6 (4.98) 77.6 (4.8) 77.3 (9.3) 69.6 (8.3)
Male: Female ratio 0.73 1.04 0.56 0.88
Smoking status
% Never smoked 41.5% 49.5% 44.1% 50.3%
% Previously smoked 47.9% 44.4% 46.0% 41.7%
% Currently smoke 10.6% 6.1% 5.4% 5.0%
% Smoking Unknown 0% 0% 4.5% 3.0%
Race
% White, non-Hispanic 99.0% 0.9495 98.9% 99.3%
% White, Hispanic 0% 0 1.1% 0.3%
% White, Unknown 0% 0 0% 0.3%
% Black, non-Hispanic 0. 5% 5.0% 0% 0%
% Other 0.5% 0% 0% 0%
            The proportions of age related macular degeneration (AMD) subtypes, gender, age, and race are shown.
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2812from all subjects, and the study was performed in accordance
with the Helsinki declaration. Diagnosis was determined by
review of fundus photographs as previously described [6].
Briefly, all subjects diagnosed with AMD had large drusen or
more advanced findings, and controls had five or fewer hard
drusen without pigment changes or more advanced findings.
SNPs for replication were genotyped using either Illumina or
TaqMan  assays  (Applied  Biosystem,  Foster  City,  CA)  as
previously described [11,21,26]. A log-additive model using
logistic  regression  was  used  for  single  SNP  association
analysis.
Quality-control filters: Quality-control filters were applied to
the SNPs from the AREDS GWAS before the assessment of
association with AMD. SNPs with a call rate less than 95%,
HWE p values based on controls <1×10−7, and SNPs with a
minor  allele  frequency  less  than  1%  were  removed  from
further analyses. Among 593 subjects, three subjects were
further  excluded,  as  they  were  considered  possible  first-
degree relatives to the remaining subjects, based on pairwise
identities  determined  by  state  calculations.  Ninety-five
percent of the SNPs passed the quality-control filters, leaving
103,895 SNPs for analysis.
Population  stratification:  Assessment  of  population
stratification was performed using a principal components
method [28] with the SNPs that passed our quality-control
thresholds across the genome found on the 100K Illumina
SNP panel. Principal component analysis was first completed
using all cases and controls for all races (n=590), followed by
an analysis including only subjects whose self-reported race
was white, non-Hispanic (n=576). All further analyses were
corrected for the first two principal components.
Genome-wide analysis: Single SNP analyses were performed
using R, PLINK, and SAS version 9.1 (SAS Institute Inc.,
Cary,  NC).  Log-additive  models  using  logistic  regression
were performed to examine the association between single
SNPs  and  AMD  status,  as  this  protected  against  finding
positive  associations  due  only  to  differences  in  the
heterozygote genotype frequencies between the AMD cases
and controls [26]. To visualize the results, quantile-quantile
(Q-Q)  plots  were  drawn  to  compare  the  distribution  of
observed p values to the expected distribution under the null
hypothesis of no association. Plots of the level of significance
of association with AMD status versus chromosomal position
(Manhattan plots) were presented to show the significance of
the SNPs across genomes.
Correction for known SNPs: We wished to determine if any
SNPs  would  be  associated  with  AMD  after  adjusting  for
known loci. The process of choosing SNPs to exclude known
loci was as follows: First, we calculated single SNP p values
for  all  SNPs  in  each  known  locus  (complement  factor  H
[CFH], complement factor I [CFI], complement component
2/complement factor B [C2/CFB], age-related maculopathy
susceptibility  2  [ARMS2],  and  complement  component  3
[C3]  loci)  after  adjusting  for  the  first  two  principal
components, and we found the most significant SNP for each
locus.  Second,  we  calculated  the  extent  of  linkage
disequilibrium (using r2) between the most significant SNP in
each locus and the rest of the SNPs in that locus to determine
if  there  were  any  significant  SNPs  not  in  high  linkage
disequilibrium (r2 less than 0.2). Third, we performed logistic
regression to see if such SNPs had any additional effect after
conditioning  on  the  most  significant  SNP  for  each  locus.
Seven SNPs were thus obtained, statistically accounting for
the genetic risk contributed to AMD by the known loci as
follows: the CFH locus, rs1853883; CFI locus, rs6848178;
C2/CFB  locus,  rs541862;  ARMS2  locus,  rs2014307  and
rs4565845; and C3 locus, rs2230199 and rs433594. The two
SNPs from the ARMS2 locus (and the C3 locus) were selected
to  represent  that  locus,  as  they  were  in  low  linkage
disequilibrium  (r2<0.2),  they  statistically  significantly
contributed to AMD, and they each made an independent
contribution  to  AMD  conditioning  on  the  other  SNP.  To
understand  the  independent  genetic  effects  within  the
ARMS2  locus  (and  C3  locus),  haplotype  analyses  were
performed for using the score test implemented in R package
haplo.stats  [29].  We  then  repeated  the  GWAS  analysis,
performing single SNP analyses with adjustments for these
seven SNPs and the first two principal components.
Smoking interaction: For assessment of the interaction effect
of SNPs significantly associated with AMD and smoking
status, a logistic regression model under a log-additive genetic
model was used, in which each significant SNP and smoking
status were included in the main effects. An interaction effect
for SNP smoking was also included, after adjusting for the
first two principal components. Smoking status was coded as
1 if the subject was a former smoker or current smoker at the
beginning of the study, or was coded as 0 if the subject had
never smoked. The distribution of smokers is shown in Table
1.
RESULTS
Questionable controls had greater similarity to controls than
to cases: The risk allele frequencies in the 27 questionable
control subjects were compared to the other control and AMD
subtypes using a two-sample test for equality of proportions
(Figure 1). The risk allele frequencies in the questionable
control group were very similar to those from the control
group,  but  not  from  the  cases.  P  values  comparing
questionable controls to control groups varied from 0.48 to 1,
while those comparing them to cases varied from 1.04×10−5
to 0.06. Thus, the questionable controls could be combined
with the controls for subsequent analyses.
Population  stratification:  To  explore  possible  population
stratification, a principal components approach was used to
assess population stratification in all subjects and in those who
self-reported  their  race  as  white,  non-Hispanic  (Table  1).
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2813Figure 2 shows a plot of the first two principal components,
which discriminated blacks from non-Hispanic whites, with
the  exception  of  one  self-defined  black  subject.  The  two
individuals with unspecified race clustered close to the non-
Hispanic whites. The figure shows that there was potential
population  stratification  among  the  white,  non-Hispanic
subjects. For further analyses, we used subjects who self-
reported as white, and corrected for population stratification
among the white subjects.
Genome-wide analysis: The association between each SNP
and AMD risk was investigated under the log-additive genetic
model. Figure 3 shows Q-Q plots of the association p values
under four different scenarios. The Q-Q plot using all subjects
(3A)  clearly  shows  population  stratification  with  an
unacceptably high genomic inflation factor of 1.23. Using
only  white  subjects  and  after  adjusting  for  the  first  two
principal  components  (Figure  3C),  the  genomic  inflation
factor was reduced to an acceptable level of 1.014. Figure 3D
shows that there is evidence for additional SNPs associated
with AMD after correction for SNPs already known to be
associated with AMD. All seven SNPs were incorporated into
a logistic regression model to correct for known association.
Figure 4 shows the distribution of p values across the genome;
individual SNPs with p values less than 0.00001 are labeled,
and additional information is provided in Table 2.
Association of individual SNPs with AMD: SNPs associated
with AMD at a p value of less than 0.0001 before or after
adjustment for SNPs already known to be associated with
AMD are shown in Table 2. Note that we did not include any
SNPs from known loci. There were 26 SNPs meeting these
criteria before adjustment and nine SNPs after adjustment; six
SNPs met both criteria. Replication in an independent group
of subjects was attempted for all SNPs. Only one SNP reached
nominal significance (CTRB locus) in the replication subject
group,  but  the  p  value  (0.02)  would  not  be  considered
significant after Bonferroni correction for multiple testing.
The value of incorporating population stratification and using
the log-additive model is illustrated by the SNP (rs2230199)
in C3 in Table 2, which reached the statistical significance
threshold  (p<0.0001)  only  after  correction  of  population
stratification and using a log-additive genetic model (Fisher’s
exact test; p=0.00048).
Interaction between smoking and SNPs associated with AMD:
Smoking was not associated with early AMD (OR=0.58, 95%
CI=0.18–1.80. The p value equaled 0.34, but was associated
with  geographic  atrophy  (OR=1.62,  95%  CI=1.07–2.44,
p=0.02),  exudative  AMD  (OR=1.51,  95%  CI=1.00–2.26,
p=0.05), and advanced AMD (OR=1.56, 95% CI=1.10–2.22,
p=0.01)  compared  to  control  groups  among  the  AREDS
GWAS  subjects.  The  replication  sample  showed  similar
results: early AMD (OR=0.87, 95% CI=0.60–1.25, p=0.45),
geographic atrophy (OR=1.68, 95% CI=0.97–2.92, p=0.06),
exudative AMD (OR=1.75, 95% CI=1.18–2.58, p=0.005),
and advanced AMD (OR=1.73, 95% CI=1.22–2.46, p=0.002).
All 59 SNPs associated with AMD at p values less than 0.0001
or  already  known  to  be  associated  were  investigated  for
possible  interactions  with  smoking  status.  Five  SNPs
(rs11208590,  rs572515,  rs7529589,  rs12038333,  and
rs203674) reached nominal significance levels (with p values
varying from 0.02 to 0.01), but none of the interactions would
Figure 1. Comparison of the frequency
of  the  risk  allele  for  four  single
nucleotide  polymorphisms  (SNPs)
known  to  contribute  to  age-related
macular  degeneration  (AMD)  in  the
age-related eye disease study (AREDS)
“control”  and  “questionable  control”
subjects. Each of these SNPs has been
consistently  associated  with  AMD  in
multiple studies. The figure shows that
the questionable control category was
similar to the control category in terms
of  the  frequency  of  the  risk  allele.
Questionable  control  subjects  can  be
used as controls in analyses using the
AREDS data set. Abbreviations: RCA is
the regulation of complement activation
locus  containing  the  gene  encoding
CFH; please see introduction for other
gene and locus names.
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2814be  considered  significant  after  Bonferroni  correction  for
multiple testing.
Independent genetic effects within the ARMS2 and C3 loci:
We  observed  statistically  independent  effects  of  both
rs4565845  and  rs2014307  across  the  ARMS2  locus  at
chromosome  10q26  (see  Correction  for  known  SNPs  in
Methods  section).  SNP  rs4565845  is  located  within  the
pleckstrin homology domain-containing family A member 1
(PLEKHA1)  gene,  while  rs2014307  is  located  between
LOC387715  and  the  high-temperature  requirement  A-1
(HTRA1) promoter. We inspected the haplotypes formed by
the six SNPs genotyped in the AREDS GWAS (rs4146894,
rs4752692,  rs4565845,  rs7097701,  rs2292623,  and
rs2014307)  across  62  kb  of  the  10q26  locus  (PLEKHA1-
LOC387715-HTRA1  promoter).  The  SNP  most  highly
associated  with  AMD  was  rs2014307,  which  captures
information from both risk and protective haplotypes across
the ARMS2 locus. Formation of haplotypes with and without
rs4752692 did not appear to lead to any refinement of the
association  of  haplotypes  with  AMD.  Specifically,  the
addition of rs4752692 split the haplotype formed by the other
five SNPs (GC-TAC) that were highly associated with AMD
(p=7.4×10−12) into two haplotypes (GCCTAC, 3.1×10−7 and
GCATAC, 1.0×10−4) that were both associated with AMD.
We also observed independently, statistically significant
effects of two SNPs (rs433594 and rs2230199) across the
C3 locus. The non-synonymous SNP rs2230199 forms a high-
risk  haplotype  with  another  non-synonymous  SNP
(rs1047286), and the effects of these two SNPs cannot be
clearly distinguished [12]. SNP rs433594 is only modestly
associated  with  AMD  in  the  AREDS  GWAS  (p=0.01).
However, four SNPs in this region near exon 19 (rs237554,
rs423490, rs433594, and rs428453) form a haplotype (GGTC;
with a frequency of 0.1 in cases and 0.18 in controls) that is
associated with AMD (p=3×10−4) at a level similar to the non-
synonymous  SNP  rs2230199  (3.4×10−5).  The  GGTC
haplotype spanning exon 9 does not appear to be in linkage
disequilibrium with the haplotype tagged by rs2230199 that
spans exons 3–9.
DISCUSSION
A genome-wide scan performed on 593 subjects from the
AREDS  was  released  in  the  database  of  Genotypes  and
Phenotypes  (dbGaP)  without  an  associated  publication
describing the genetic features of the data set. The AREDS
genome-wide scan data set has been used extensively for
genetic  studies  on  AMD,  as  detailed  in  the  introduction.
Because of the ongoing analyses using the AREDS subjects
and the AREDS genome-wide scan data set, we felt that a
Figure 2. Population stratification in the
age-related eye disease study (AREDS)
subjects.  Three  race  categories  are
presented in pink circle for white, non-
Hispanics (White), in black triangle for
blacks (Black), and in green cross for
subjects  who  are  neither  white,  non-
Hispanics nor blacks. A plot of the first
two  principal  components  using
103,895  single  nucleotide
polymorphisms (SNPs) passing quality-
control filters. Of the total 590 subjects,
the self-reported race was white, non-
Hispanic  for  576,  black  for  12,  and
“other” for 2. The figure shows that one
black  subject  and  two  other  subjects
were similar to the white subjects. There
was also stratification among the white
subjects,  for  which  we  corrected  in
subsequent analyses. The x-axis shows
the  first  principal  component  axis
(PC1),  while  the  y-axis  shows  the
second component (PC2).
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2815detailed analysis of the genome-wide scan data set might
provide valuable guidance on its use in AMD research.
The AREDS data set has been studied previously in two
reports [20,26]. These studies did not analyze the data set
using the actual genotypes from the AREDS data set. Instead,
both  studies  obtained  p  values  from  the  AREDS  dbGaP
website to select the SNPs for replication studies. Herein, we
have performed a primary analysis of the AREDS data set
using standard approaches, including log-additive models and
correction for population stratification.
Prior to initiating the analysis of the genome-wide scan
data set, we sought to determine the heterogeneity within the
various categories of control subjects within the AREDS. The
phenotypic range of drusen that has been allowed for control
subjects in AMD studies has been controversial. Many groups
use an extreme phenotype approach in which only a few hard
drusen  (without  more  advanced  features  such  as  pigment
changes) are allowed in control subjects, based on fundus
photography  [6,30,31].  Other  groups  have  used  clinical
examination  without  fundus  photography  [32].  Some
Figure 3. Quantile-quantile plots of the
age-related eye disease study (AREDS)
genome-wide  association  study
(GWAS). A: Scatter plot of the −log10
(p  values)  expected  under  the  null
hypothesis  of  no  genetic  association
versus the observed −log10 (p values)
are shown for all subjects. B: This is a
scatter  plot  as  in  A,  but  for  white
subjects only. C: This is a scatter plot of
white subjects corrected for population
stratification  using  principal
components methods without exclusion
of known loci. D: This is a scatter plot
of  white  subjects  corrected  for
population stratification using principal
components methods with exclusion of
known loci. A–C: These plots show that
correction for population stratification
reduced  the  genomic  inflation  factor
from 1.23 to 1.01. D: This plot suggests
that  there  is  evidence  for  additional
single  nucleotide  polymorphisms
(SNPs)  contributing  to  age-related
macular  degeneration  (AMD)  after
statistically accounting for known loci.
Figure  4.  The  association  of  single
single  nucleotide  polymorphisms
(SNPs)  with  age-related  macular
degeneration  (AMD)  across  the
genome.  Significance  across  the
genome is illustrated by plotting −log 10
(p values) from the log-additive genetic
model  corrected  for  population
stratification. The loci with p values less
than 0.00001 are labeled and the SNPs
are provided in Table 2.
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2817investigators have argued that even the extreme phenotypes
used by many groups are not sufficiently stringent, and that
different criteria for controls could explain the failure of other
investigators to replicate genetic association in the TLR3 locus
[33,34]. However, the high prevalence of a few hard drusen
in  aged  individuals  using  both  clinical  examination  and
fundus photography suggests that more stringent criteria may
not be possible. For example, 96% of all subjects (age 43 and
older) had at least one drusen at the baseline in the Beaver
Dam Eye Study [35].
A gold standard for defining a control could be based on
clinical criteria (e.g., rate of progression to advanced disease)
or some combination of biomarkers contributing to disease
risk. Although genetic variation accounting for approximately
80%  of  the  risk  for  AMD  has  now  been  identified,  this
information was not available at the time that the AREDS
AMD severity scales were developed [36,37]. For the AREDS
genome-wide  scan  data  set,  photographic  grading  was
performed at a reading center using standardized approaches,
and  longitudinal  follow-up  detailing  rates  of  progression
allowed us to directly ask if “questionable control” subjects
were more similar to cases or to controls. Figure 1 shows that
the questionable control subjects were indistinguishable from
the controls, based on risk allele frequencies at known AMD
loci. Further, the rate of progression to advanced AMD for
questionable control subjects was extremely low [27]. Thus,
by  both  genetic  and  clinical  criteria,  questionable  control
subjects appear to be similar to controls. Our observation
would  be  most  valid  in  older  subjects  (≥60  years),  and
probably would not apply to younger individuals with a few
hard drusen that are known to be at high risk for incident AMD
[38]. Note that this observation will be useful to a variety of
researchers studying the extensive clinical and epidemiologic
data sets from the AREDS clinical trial.
We evaluated the AREDS GWAS for problems that could
lead  to  faulty  conclusions  in  genetic  association  studies.
Genetic  heterogeneity  can  inflate  the  significance  of  the
association between SNPs and disease (type I errors) [28,
39-41].  It  is  thus  standard  practice  to  perform  genetic
association  analyses  on  homogeneous  racial  populations
defined by self-reported race. Racial classifications defined
using  genetic  data  may  be  even  more  accurate  than  self-
reported race. For example, we observed individuals that did
not  fit  genetically  with  the  self-reported  race  (Figure  2).
Further, we observed residual substructure within the white
population that artificially inflated the overall association with
AMD in the AREDS GWAS (Figure 2 and Figure 3). Principal
components  methods  statistically  corrected  for  the
substructure, reducing the genomic inflation to an acceptable
level (Figure 3). Our analyses suggest that investigators using
genetic  data  from  the  AREDS  trial  should  account  for
population substructure in their studies.
Another problem in GWAS studies is the observation that
differences in heterozygote frequencies between cases and
controls can lead to type I errors, or false positive associations
[26]. Thus, we performed here an analysis using a log-additive
genetic model that is less sensitive to genotype distributions
that differ primarily by heterozygote frequencies, and that is
more sensitive to additive changes that are often used for
analyses of complex traits. However, we acknowledge the
limitation of the log-additive genetic model, which can be less
powerful if the true model is not additive. Another problem
can arise from relying on statistical tests of allele frequency
differences between subject groups. While genotype tests are
independent  of  the  Hardy–Weinberg  equilibrium  (HWE),
allele  tests  require  the  calculation  of  allele  frequencies
assuming HWE [42]. Deviation from HWE can arise from
inaccurate genotyping or copy-number variation. Thus, we
favor  statistical  models  of  inheritance  based  on  genotype
frequencies.
We  observed  statistically  independent  effects  of  two
SNPs (rs4565845 and rs2014307) across the ARMS2 locus at
chromosome  10q26  and  of  two  SNPs  (rs433594  and
rs2230199) across the C3 locus. The independent effect of
rs4565845 that we observed in the PLEKHA1 gene adjacent
to the ARMS2 locus does not seem consistent with a well
defined genomic region (e.g., haplotype). Others also have
reported  independent  association  with  AMD  in  the
PLEKHA1  region,  but  it  has  not  yet  been  possible  to
convincingly  demonstrate  an  independent  biologic  effect,
given the modest association with AMD, compared to the
strong  association  in  the  haplotype  block  spanning  the
hypothetical gene LOC387715 and the promoter of HTRA1
[43]. It is hoped that these questions will be resolved in the
future, as the biology of the ARMS2 locus becomes better
understood.
On the other hand, the independent effect of rs433594 in
the C3 gene appears to arise due to the strong association
between AMD and a haplotype spanning exon 19 of C3. The
genetic risk in the exon 19 region appears to be independent
of the established genetic risks of non-synonymous SNPs in
exons 3 and 9 of C3. Thus, it is possible that the genomic
region  spanning  exon  19  contains  a  variant  on  a  specific
haplotype  (see  Independent  genetic  effects  within  the
ARMS2 and C3 loci in Results section) that increases the risk
of AMD. Re-sequencing studies are underway that may help
address this question.
We identified 29 SNPs with p values greater than 0.0001
either before or after correction for known loci associated with
AMD (Table 2). We attempted replication by genotyping each
of these SNPs or a proxy (a nearby SNP in high linkage
disequilibrium) in a larger, independent group of controls
without  AMD  and  in  cases  with  AMD  of  similar  ethnic
background.  However,  none  of  the  SNPs  were  definitely
replicated in the independent group of subjects. Larger studies
are ongoing and will be helpful in determining if the modest
effects we observed upon replication (Table 2) and in our prior
Molecular Vision 2010; 16:2811-2821 <http://www.molvis.org/molvis/v16/a301> © 2010 Molecular Vision
2818work with the AREDS GWAS may make a minor contribution
to AMD [26]. Future work is needed to validate these results
and to determine the functional relevance of these SNPs, if
any.
Smoking is well established as a risk factor for both
incident  early  AMD  and  advanced  AMD  [44-47].  In  the
AREDS GWAS, smoking was associated with both forms of
advanced AMD only, presumably due to the stronger effect
of smoking on the development of geographic atrophy and
exudation.  There  have  been  inconsistent  reports  that  the
variants in the ARMS2 locus may mediate [48-50] or interact
[51,52] with the effect of smoking, but we did not observe an
interaction between smoking and genetic risks in the AREDS
subjects. Smoking appears to be an independent risk factor
contributing to the development of AMD.
In  summary,  we  reported  the  value  of  correcting  for
population  stratification  when  working  with  the  AREDS
GWAS and have provided evidence supporting the use of
questionable  control  subjects  as  controls  in  the  AREDS
GWAS study. Further, we presented further evidence that the
contribution  of  smoking  to  the  development  of  AMD  is
independent of genetic risks. Finally, we observed that the
AREDS  data  set  has  evidence  suggestive  of  a  previously
unknown genetic risk near exon 19 of the C3 gene. Additional
studies will be needed to determine if this observation can be
replicated. There continues to be evidence for independent
risks in the ARMS2 locus.
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